On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the approval of the clinical trial plan by the Institutional Review Board (IRB) at Clinical Pharmacology of Miami for the company's Phase 1 ...
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Multiple Presentations for DA-1726 and Vanoglipel at ADA 2026 On June 8, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the presentation of new ...
DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, MetaVia, Inc. (NASDAQ:MTVA) announced that the company has extended the 48 mg multiple ascending dose (MAD) cohort of the Phase 1 ...
Treatment with DA-1726 Shows No Evidence of Cardiovascular Changes On May 26, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the presentation of new Phase 1 data for DA-1726, the company’s oxyntomodulin ...
Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Ascending Dose Part 2 in the First Quarter of 2025 Planned Part 3 Will Assess ...
Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of ...
Mr. Kim concluded, "We continue to believe that DA-1726's 3:1 balanced activation of GLP-1 and glucagon receptors offers a promising alternative to current GLP-1 agonists, addressing significant ...
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results